6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advances in nanomaterial-targeted treatment of acute lung injury after burns

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          To summarize the mechanisms and pathophysiological features of ALI after burn.

          To classify the targets for the treatment of ALI.

          Describe the types of nanomedicines used to treat ALI.

          These findings suggest the prospects and outlook for nanomaterial-targeted therapy for ALI.

          Abstract

          Acute lung injury (ALI ) is a common complication in patients with severe burns and has a complex pathogenesis and high morbidity and mortality rates. A variety of drugs have been identified in the clinic for the treatment of ALI, but they have toxic side effects caused by easy degradation in the body and distribution throughout the body. In recent years, as the understanding of the mechanism underlying ALI has improved, scholars have developed a variety of new nanomaterials that can be safely and effectively targeted for the treatment of ALI. Most of these methods involve nanomaterials such as lipids, organic polymers, peptides, extracellular vesicles or cell membranes, inorganic nanoparticles and other nanomaterials, which are targeted to reach lung tissues to perform their functions through active targeting or passive targeting, a process that involves a variety of cells or organelles. In this review, first, the mechanisms and pathophysiological features of ALI occurrence after burn injury are reviewed, potential therapeutic targets for ALI are summarized, existing nanomaterials for the targeted treatment of ALI are classified, and possible problems and challenges of nanomaterials in the targeted treatment of ALI are discussed to provide a reference for the development of nanomaterials for the targeted treatment of ALI.

          Related collections

          Most cited references99

          • Record: found
          • Abstract: found
          • Article: not found

          Acute lung injury and the acute respiratory distress syndrome: a clinical review.

          Acute respiratory distress syndrome and acute lung injury are well defined and readily recognised clinical disorders caused by many clinical insults to the lung or because of predispositions to lung injury. That this process is common in intensive care is well established. The mainstay of treatment for this disorder is provision of excellent supportive care since these patients are critically ill and frequently have coexisting conditions including sepsis and multiple organ failure. Refinements in ventilator and fluid management supported by data from prospective randomised trials have increased the methods available to effectively manage this disorder.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Targeting immunometabolism as an anti-inflammatory strategy

              The growing field of immunometabolism has taught us how metabolic cellular reactions and processes not only provide a means to generate ATP and biosynthetic precursors, but are also a way of controlling immunity and inflammation. Metabolic reprogramming of immune cells is essential for both inflammatory as well as anti-inflammatory responses. Four anti-inflammatory therapies, DMF, Metformin, Methotrexate and Rapamycin all work by affecting metabolism and/or regulating or mimicking endogenous metabolites with anti-inflammatory effects. Evidence is emerging for the targeting of specific metabolic events as a strategy to limit inflammation in different contexts. Here we discuss these recent developments and speculate on the prospect of targeting immunometabolism in the effort to develop novel anti-inflammatory therapeutics. As accumulating evidence for roles of an intricate and elaborate network of metabolic processes, including lipid, amino acid and nucleotide metabolism provides key focal points for developing new therapies, we here turn our attention to glycolysis and the TCA cycle to provide examples of how metabolic intermediates and enzymes can provide potential novel therapeutic targets.
                Bookmark

                Author and article information

                Contributors
                xianwenwang@ahmu.edu.cn
                okcxl@126.com
                Journal
                J Nanobiotechnology
                J Nanobiotechnology
                Journal of Nanobiotechnology
                BioMed Central (London )
                1477-3155
                18 June 2024
                18 June 2024
                2024
                : 22
                : 342
                Affiliations
                [1 ]Department of Burns, The First Affiliated Hospital of Anhui Medical University, ( https://ror.org/03t1yn780) Hefei, 230022 P. R. China
                [2 ]School of Biomedical Engineering, Anhui Medical University, ( https://ror.org/03xb04968) Hefei, 230022 P. R. China
                Article
                2615
                10.1186/s12951-024-02615-0
                11184898
                38890721
                508e9948-55a0-4bf8-8e76-3d4f393371ee
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 30 April 2024
                : 4 June 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 52202343, 82172204
                Funded by: the Research Fund of Anhui Institute of Translational Medicine
                Award ID: 2022zhyx-C01
                Funded by: the Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University
                Award ID: 2021xkT028
                Funded by: the Anhui Key Research and Development Plan
                Award ID: 202104j07020027
                Categories
                Review
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                Biotechnology
                ali,nanomaterials,burn,targeted treatment,camouflaged nanoparticles
                Biotechnology
                ali, nanomaterials, burn, targeted treatment, camouflaged nanoparticles

                Comments

                Comment on this article